Table 1.

Molecular target(s), solvents and concentrations of drugs that were applied.

Drug	Target and Reference	Solvent	Stock Concentration	Concentration and number of samples
Conolidine	this study	DMSO	37.5 mM	30 µM (n = 18)
Cannabidiol	this study + Cav3.1, 3.2, 3.3 (T-Type) channel blocker40, CB1, CB2 cannabinoid receptor antagonist13, µ and δ opioid receptor modulator14	DMSO	75 mM	10 µM (n = 18)
Baclofen	G protein-coupled gamma-aminobutyric acid (GABA) type B (GABAB) receptor agonist42	1 M NaOH	100 mM	1 µM43 (n = 18)
Bicuculline	GABAA receptor antagonist44	DMSO	100 mM	20 µM45 (n = 18)
Carbamazepine	Na+ channel blocker46	DMSO	100 mM	10 µM47 (n = 18)
Morphine	µ-δ opioid receptor agonist48	H2O	50 mM	10 µM (n = 18)49
ω-conotoxin CVIE	Cav2.2 (N-type) channel blocker28	H2O	—	100 nM (n = 18)28
Diazepam	GABAA receptor positive allosteric modulator	DMSO	100 mM	1 µM50 (n = 18)
LY341495	Metabotropic glutamate (mGlu) receptor antagonist51	DMSO	100 mM	5 µM51 (n = 18)
Nickel (Ni2+)	Cav3.1, Cav3.2 and Cav3.3 (T-type) channel blocker52	H2O	100 mM	200 µM52 (n = 18)
ZD7288	HCN channel blocker53	DMSO	100 mM	20 µM54 (n = 16)